Rxilient Biotech and Junshi Biosciences partner to develop and commercialize Toripalimab
On 28th March 2023, Rxilient Biotech (a portfolio company of Legend Capital) and Junshi Biosciences made a joint announcement that two parties will form a joint venture to develop and commercialize toripalimab in Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam. Toripalimab is an anti-PD-1 monoclonal antibody independently developed by Junshi Biosciences. […]
